Literature DB >> 19332712

CALGB 9633: an underpowered trial with a methodologically questionable conclusion.

Artur Katz, Everardo D Saad.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19332712     DOI： 10.1200/JCO.2008.21.1565

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Neoadjuvant versus adjuvant chemotherapy for resectable non-small cell lung cancer debate revisited.

Authors:  Chan Yeu Pu; Sai Yendamuri
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

2.  Adjuvant Chemotherapy After Lobectomy for T1-2N0 Non-Small Cell Lung Cancer: Are the Guidelines Supported?

Authors:  Paul J Speicher; Lin Gu; Xiaofei Wang; Matthew G Hartwig; Thomas A D'Amico; Mark F Berry
Journal:  J Natl Compr Canc Netw       Date:  2015-06       Impact factor: 11.908

3.  Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib.

Authors:  Shannon S Zhang; Sai-Hong Ignatius Ou
Journal:  Lung Cancer (Auckl)       Date:  2022-04-26

4.  MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma.

Authors:  Wei Meng; Zhenqing Ye; Ri Cui; James Perry; Vaia Dedousi-Huebner; Alexander Huebner; Yao Wang; Bin Li; Stefano Volinia; Hiroshi Nakanishi; Taewan Kim; Sung-Suk Suh; Leona W Ayers; Patrick Ross; Carlo M Croce; Arnab Chakravarti; Victor X Jin; Tim Lautenschlaeger
Journal:  Clin Cancer Res       Date:  2013-08-14       Impact factor: 12.531

5.  Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.

Authors:  Raphael Bueno; Elisha Hughes; Susanne Wagner; Alexander S Gutin; Jerry S Lanchbury; Yifan Zheng; Michael A Archer; Corinne Gustafson; Joshua T Jones; Kristen Rushton; Jennifer Saam; Edward Kim; Massimo Barberis; Ignacio Wistuba; Richard J Wenstrup; William A Wallace; Anne-Renee Hartman; David J Harrison
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.